首页> 美国卫生研究院文献>Oncology Letters >High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer
【2h】

High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer

机译:miR-155和miR-21在非小细胞肺癌复发或转移中的高表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer (NSCLC) was investigated. Retrospective analysis on the clinical information of 180 patients with NSCLC was carried out. The patients were admitted to Daqing Oil Field General Hospital from February 2012 to March 2015 and they were the research group. Moreover, the physical examination information of 88 normal medical examinees were selected at the same period of time as the control group. In the research group, 68 patients diagnosed with NSCLC were the newly diagnosed group and 112 cases of recurrence or metastasis of NSCLC were the recurrence group. The quantitative real-time polymerase chain reaction was used to detect the expression levels of serum miR-115 and miR-21. In addition, the expression levels between miR-155 and miR-21 and the relationship between the recurrence rate and metastasis of NSCLC were analyzed. The impact on the prognosis of patients were also analyzed. The expression levels of serum miR-155 and miR-21 were higher in the research group than those in the control group (P<0.05). The expression levels of serum miR-155 and miR-21 were higher in the recurrence group than those in the newly diagnosed group (P<0.05). We followed up the patients in the research group for 36 months, the median survival time and mortality rate in the recurrence group was higher than that of in the newly diagnosed group (χ2=9.705, P<0.01). In conclusion, miR-155 and miR-21 were highly expressed in the serum of patients, however, the recurrence and metastasis of NSCLC were even higher. The highly expressed levels of miR-155 and miR-21 were associated with the recurrence and metastasis in NSCLC patients, affecting the prognosis of patients.
机译:研究了miR-155和miR-21在非小细胞肺癌(NSCLC)复发或转移中的高表达。回顾性分析180例NSCLC患者的临床资料。该患者为研究组,于2012年2月至2015年3月入住大庆油田总医院。此外,在与对照组相同的时间段内选择了88名正常医学检查者的身体检查信息。在研究组中,新诊断组为68例确诊为NSCLC的患者,复发组为112例NSCLC复发或转移的患者。实时定量聚合酶链反应用于检测血清miR-115和miR-21的表达水平。此外,分析了miR-155和miR-21之间的表达水平以及NSCLC的复发率与转移之间的关系。还分析了对患者预后的影响。研究组血清miR-155和miR-21的表达水平高于对照组(P <0.05)。复发组血清miR-155和miR-21的表达水平高于初诊组(P <0.05)。我们对研究组的患者进行了36个月的随访,复发组的中位生存时间和死亡率均高于新诊断组(χ 2 = 9.705,P <0.01 )。总之,miR-155和miR-21在患者血清中高表达,但NSCLC的复发和转移率更高。 miR-155和miR-21的高表达水平与NSCLC患者的复发和转移有关,影响患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号